CSPC’s EGFR ADC SYS6010 Beats Chemotherapy in Phase 3 NSCLC Trial, Setting Stage for Potential Regulatory Filing

August 28, 2026 8 Min Read

CSPC Pharmaceutical Group’s experimental EGFR-targeting antibody-drug conjugate SYS6010 has met the primary endpoint in the pivotal Phase III SYNSTAR-01 trial, significantly improving progression-free survival over platinum-based chemotherapy in patients with EGFR-mutated non-small cell lung cancer whose disease progressed following EGFR tyrosine kinase inhibitor therapy.

The positive trial represents an important milestone for CSPC Pharmaceutical Group (HKEX: 1093) as it attempts to establish SYS6010 as a broadly applicable EGFR-targeted ADC across lung, breast, esophageal and head-and-neck cancers.

According to CSPC’s August 26 announcement, an independent Data Monitoring Committee concluded at a prespecified interim analysis that SYS6010 produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with platinum-based chemotherapy. (doc.irasia.com)

The study also showed a positive trend in overall survival (OS), while CSPC described SYS6010’s overall safety profile as favorable. Numerical PFS, OS and hazard-ratio data have not yet been disclosed. (doc.irasia.com)

The result comes just weeks after Phase I data for SYS6010 were published in Cancer Cell – SYS6010 Phase I Study, providing the most detailed clinical evidence to date supporting CSPC’s rapidly expanding development program for the ADC. (pubmed.ncbi.nlm.nih.gov)

SYNSTAR-01 at a Glance

Study	SYNSTAR-01
Drug	SYS6010
Modality	EGFR-targeting ADC
Phase	Phase III
Population	EGFR-mutated locally advanced/metastatic NSCLC after EGFR TKI failure
Design	Randomized, open-label, multicenter
Experimental arm	SYS6010 monotherapy
Control	Platinum-based chemotherapy
Planned enrollment	~380 patients
Primary endpoint	PFS by Independent Review Committee
PFS result	Met — statistically significant and clinically meaningful improvement
OS	Positive benefit trend
Safety	Described by CSPC as favorable
Detailed results	Not yet disclosed

The trial registry lists approximately 380 participants and compares SYS6010 against pemetrexed plus cisplatin or carboplatin. (clinicaltrials.gov)

Addressing EGFR TKI Resistance

SYNSTAR-01 targets a major treatment challenge in EGFR-mutated lung cancer.

EGFR TKIs have transformed treatment for patients whose tumors harbor actionable EGFR mutations. However, resistance eventually develops, leaving patients requiring additional systemic therapy.

CSPC estimates that NSCLC accounts for approximately 85% of lung cancers, with EGFR mutations occurring in roughly 40%–50% of NSCLC patients in mainland China. (doc.irasia.com)

SYS6010 takes a fundamentally different approach from another EGFR kinase inhibitor.

Rather than attempting primarily to inhibit EGFR signaling, the ADC uses EGFR expression on cancer cells as a delivery address for a potent cytotoxic payload.

That strategy could potentially allow SYS6010 to remain active even after tumors develop resistance to EGFR TKIs through mechanisms that reduce their dependence on EGFR signaling.

The Phase III result now provides randomized evidence that this approach can translate into superior disease control compared with platinum chemotherapy in the post-TKI setting.

How SYS6010 Works

SYS6010 is an EGFR-targeting antibody-drug conjugate developed by CSPC’s Megalith Biopharmaceutical subsidiary.

Its basic architecture consists of:

Humanized anti-EGFR antibody → cleavable linker → JS-1 topoisomerase-I inhibitor payload

CSPC says SYS6010 binds EGFR on the tumor-cell surface, after which the ADC is internalized and degraded in the lysosome, releasing its cytotoxic payload inside the cancer cell. (doc.irasia.com)

The payload, JS-1, is a proprietary topoisomerase-I inhibitor that induces DNA damage and ultimately tumor-cell death. It is also membrane permeable, enabling a bystander effect that may kill nearby tumor cells even when EGFR expression is heterogeneous. (www1.hkexnews.hk)

SYS6010 component	Characteristics
Target	EGFR
Antibody	Humanized anti-EGFR IgG1
Linker	Cleavable linker
Payload	JS-1
Payload mechanism	Topoisomerase-I inhibition
Drug-to-antibody ratio	DAR ≈ 8
Additional property	Bystander killing through membrane-permeable payload

CSPC’s Hong Kong listing materials describe SYS6010 as having a drug-to-antibody ratio of 8. (www1.hkexnews.hk)

Phase I Data Provide Clinical Foundation

The Phase III success follows publication of the first large peer-reviewed SYS6010 clinical dataset.

The Phase I study, published online in Cancer Cell on August 13, evaluated SYS6010 in 236 patients with NSCLC. (pubmed.ncbi.nlm.nih.gov)

One dose-limiting toxicity occurred at 6.4 mg/kg, and doses of 4.2, 4.5 and 4.8 mg/kg were selected for cohort expansion.

Importantly, antitumor activity was observed across several NSCLC populations.

NSCLC population	Objective response rate
EGFR-mutant, prior EGFR TKI	45.7%
EGFR-mutant, prior EGFR TKI + platinum chemotherapy	34.7%
EGFR wild-type squamous NSCLC	20.0%
EGFR wild-type non-squamous NSCLC	35.7%

Among patients with EGFR-mutant NSCLC previously treated with EGFR TKIs, the ORR reached 45.7%. (pubmed.ncbi.nlm.nih.gov)

In the more heavily pretreated population whose tumors had progressed after both EGFR TKI and platinum chemotherapy, SYS6010 produced a 34.7% ORR, with median PFS of 7.6 months and median OS of 19.4 months. (pubmed.ncbi.nlm.nih.gov)

The results suggested SYS6010 retained clinically meaningful activity even after patients had exhausted both targeted therapy and conventional platinum chemotherapy.

Safety Profile

The Phase I publication also provides important context for CSPC’s characterization of the Phase III safety profile as favorable.

Across the 236 Phase I patients, treatment-related adverse events occurred in 99.6%, while Grade 3 or higher treatment-related adverse events occurred in 57.2%. (pubmed.ncbi.nlm.nih.gov)

The most common Grade ≥3 treatment-related adverse events included:

Neutropenia — 30.9%
Leukopenia — 25.0%
Thrombocytopenia — 17.4%

The investigators concluded that SYS6010 demonstrated a manageable safety profile alongside encouraging antitumor activity in previously treated advanced NSCLC. (pubmed.ncbi.nlm.nih.gov)

Full SYNSTAR-01 safety data will be important for determining whether that profile remains favorable in a larger randomized population.

From Phase I to Phase III at High Speed

SYS6010 has become one of CSPC’s most aggressively developed oncology assets.

The company completed enrollment of SYNSTAR-01 in February 2026, and the prespecified interim analysis has now delivered a positive result only months later. (financialfilings.com)

But CSPC is pursuing a considerably broader strategy than the initial EGFR-mutant NSCLC indication.

Public trial registries and CSPC disclosures show Phase III development expanding across multiple NSCLC settings as well as breast cancer, esophageal squamous cell carcinoma and head-and-neck squamous cell carcinoma. (clinicaltrials.gov)

Expanding SYS6010 Phase III Program

Setting	Phase III strategy
EGFR-mutant NSCLC after TKI failure	SYS6010 vs platinum chemotherapy — SYNSTAR-01, positive PFS
EGFR-mutant NSCLC	SYS6010 + osimertinib
Previously treated EGFR wild-type NSCLC	SYS6010 vs docetaxel
Driver-negative PD-L1+ advanced NSCLC	SYS6010 + enlonstobart
Resected driver-negative NSCLC	SYS6010 + enlonstobart as adjuvant therapy
HER2-negative, EGFR-positive breast cancer	SYS6010 vs investigator-choice chemotherapy
Esophageal squamous cell carcinoma	SYS6010 vs chemotherapy
Recurrent/metastatic HNSCC	SYS6010 vs investigator-choice monotherapy

The breadth of the program shows that CSPC increasingly views SYS6010 not merely as an EGFR-mutant lung cancer drug, but as a potential pan-tumor EGFR ADC franchise.

Seven New Phase III Programs in 2026

The development pace has accelerated dramatically this year.

SYNSTAR-01 began earlier, while CSPC has moved a series of additional SYS6010 programs into Phase III during 2026.

For example, a Phase III trial in HER2-negative, EGFR-positive recurrent or metastatic breast cancer plans to enroll approximately 400 patients and compare SYS6010 against investigator-selected chemotherapy. (clinicaltrials.gov)

A separate Phase III study is evaluating SYS6010 in recurrent or metastatic head and neck squamous cell carcinoma, with approximately 340 patients planned. (clinicaltrials.gov)

CSPC has also initiated Phase III studies combining SYS6010 with its PD-1 antibody enlonstobart in driver-negative NSCLC, including both advanced disease and the postsurgical adjuvant setting. (money.finance.sina.com.cn, cspc.com.hk)

This rapid expansion represents a major commitment of clinical-development resources to the molecule.

Beyond EGFR-Mutant Lung Cancer

One of the most interesting findings from the Phase I study was activity outside classical EGFR-mutant disease.

SYS6010 generated a 35.7% ORR in EGFR wild-type non-squamous NSCLC and a 20.0% ORR in EGFR wild-type squamous NSCLC. (pubmed.ncbi.nlm.nih.gov)

That observation supports the biological rationale behind CSPC’s broader development strategy.

For an EGFR TKI, an activating EGFR mutation is typically fundamental to therapeutic activity.

For an EGFR ADC, however, the receptor can instead function as a tumor-associated antigen used to deliver the payload.

The therapeutic question therefore shifts from:

“Is the tumor driven by an EGFR mutation?”

to:

“Can EGFR expression provide sufficient selective delivery of the cytotoxic payload?”

If the latter hypothesis continues to hold in randomized trials, SYS6010’s addressable population could extend well beyond EGFR-mutated NSCLC.

Breast Cancer, Esophageal Cancer and HNSCC

That concept is already being tested outside lung cancer.

The breast cancer Phase III study enrolls patients with HER2-negative, EGFR-positive unresectable recurrent or metastatic breast cancer following prior chemotherapy. Approximately 400 participants are planned, with SYS6010 compared against standard agents including eribulin, capecitabine, gemcitabine or vinorelbine. (clinicaltrials.gov)

In esophageal squamous cell carcinoma, SYS6010 has also advanced into Phase III development, while CSPC announced in June that the molecule received another Chinese Breakthrough Therapy Designation for locally advanced or metastatic ESCC. (findtrial.co, cspc.com.hk)

And in August, a new Phase III trial was registered evaluating SYS6010 against investigator-choice monotherapy in approximately 340 patients with recurrent or metastatic HNSCC. (clinicaltrials.gov)

Together, these programs test whether EGFR can serve as an ADC target across multiple epithelial cancers.

An Increasingly Competitive EGFR-ADC Field

SYS6010 is advancing as interest in EGFR-targeted ADCs accelerates.

The target is attractive because EGFR is highly expressed across multiple epithelial malignancies, yet developing effective antibody-based therapies against it has historically been challenging because EGFR is also present in normal tissues.

ADC engineering therefore becomes particularly important: antibody affinity, internalization, linker stability, payload potency, drug-to-antibody ratio and bystander activity can all influence the therapeutic window.

SYS6010 uses a DAR of approximately eight and the proprietary TOP1 payload JS-1, placing it within the rapidly expanding class of high-DAR topoisomerase-I ADCs. (www1.hkexnews.hk)

CSPC has not, however, characterized SYS6010 in its current public clinical disclosures as a specifically pH-dependent-affinity engineered antibody. Public patent materials describe CSPC/JMT work involving both BA03 and separate pH-dependent anti-EGFR antibodies, so attributing that property directly to clinical-stage SYS6010 should be treated cautiously unless confirmed by the company or the clinical publication. (foxrothschild.gjassets.com)

What Happens Next?

The immediate focus will be on detailed SYNSTAR-01 data.

CSPC has so far disclosed only the topline conclusions:

PFS: statistically significant and clinically meaningful improvement versus platinum chemotherapy.

OS: positive benefit trend.

Safety: favorable overall profile. (doc.irasia.com)

The magnitude of the PFS benefit, hazard ratio, median PFS values, response rate, duration of response and detailed adverse-event profile have not yet been publicly reported.

Those numbers will ultimately determine how strongly SYS6010 differentiates itself from existing post-EGFR-TKI treatment options.

The OS trajectory will be particularly important. At interim analysis, CSPC reported only a trend toward benefit rather than a statistically significant OS result. Longer follow-up may determine whether the PFS advantage translates into improved survival. (doc.irasia.com)

Outlook

The positive SYNSTAR-01 readout represents the strongest clinical validation yet for SYS6010.

Phase I data had already demonstrated encouraging activity, including a 45.7% response rate in EGFR-mutant NSCLC following EGFR TKI therapy and median PFS of 7.6 months with median OS of 19.4 months in the more heavily pretreated post-TKI/post-platinum population. (pubmed.ncbi.nlm.nih.gov)

SYNSTAR-01 now moves the evidence from an early-stage single-arm setting into a randomized Phase III comparison and shows that SYS6010 can significantly outperform platinum-based chemotherapy on PFS after EGFR TKI failure. (doc.irasia.com)

For CSPC, the implications extend beyond a single lung cancer indication.

The company is executing an unusually broad Phase III strategy across NSCLC, breast cancer, ESCC and HNSCC. If additional studies succeed, SYS6010 could evolve from a post-EGFR-TKI lung cancer therapy into a much larger EGFR-directed ADC franchise spanning multiple solid tumors.

The result also adds to the rapidly growing body of evidence emerging from China’s ADC industry. Chinese developers are no longer simply advancing early clinical candidates or licensing molecules abroad; an increasing number of domestically developed ADCs are now generating randomized Phase III evidence across major tumor types.

For SYS6010, the next milestones will be full disclosure of the SYNSTAR-01 dataset, maturation of overall survival, and the regulatory strategy that follows the positive pivotal result.

With one Phase III study now positive and a broad portfolio of additional pivotal studies underway, SYS6010 has become one of the most important late-stage assets in CSPC’s oncology pipeline—and potentially one of the leading tests of whether EGFR can emerge as a broadly useful ADC target beyond classical EGFR-driven disease.

References

Tags: